Bluejay Diagnostics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 9, 2026, specifically the Company's 2026 Annual Meeting of Stockholders. Bluejay Diagnostics, Inc. is an emerging growth company incorporated in Delaware with its principal executive offices in Acton, MA. The Company's common stock trades on The Nasdaq Capital Market under the symbol BJDX.
Key Financial Metrics
This filing is a current report regarding corporate governance and stockholder actions; it does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing notes that as of the record date (April 28, 2026), there were 1,034,715 shares of common stock issued and outstanding. On the date of the meeting (June 9, 2026), the closing stock price was $4.50.
Material Changes and Corporate Actions
Stockholders approved three significant proposals at the Annual Meeting:
- Reverse Stock Split Authorization: Stockholders approved an amendment to the certificate of incorporation to effect a reverse stock split at a ratio between 1-for-2 and 1-for-20. The Board retains sole discretion to determine the timing and exact ratio, with no present intention to implement the split within the next 12 months. This measure is intended to provide flexibility to maintain compliance with Nasdaq's $1.00 minimum bid price requirement should the stock price decline significantly.
- Stock Plan Amendment: The number of shares reserved for issuance under the 2021 Stock Plan was increased by 600,000 shares, raising the total from 61 shares to 600,061 shares.
- Director Elections: Stockholders re-elected Donald Chase, Neil Dey, Svetlana Dey, Douglas Wurth, and Fred Zeidman to the Board of Directors.
- Auditor Ratification: Wolf & Company, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or management commentary on operational outlook. The primary risk context provided relates to the Reverse Stock Split, which was approved as a contingency measure to address potential future non-compliance with Nasdaq listing standards if the stock price falls below the minimum bid price. The Company confirmed it was in full compliance with all Nasdaq listing requirements as of June 9, 2026.
Key Facts for Investor Verification
- Verify the current trading price of BJDX relative to the $1.00 Nasdaq minimum bid price requirement to assess the likelihood of the Board exercising the reverse stock split option.
- Confirm the total number of shares outstanding (1,034,715 as of April 28, 2026) and monitor for any future announcements regarding the implementation of the reverse stock split.
- Review the amended 2021 Stock Plan (Exhibit 10.1) to understand the dilution impact of the newly authorized 600,000 shares.
- Note that the Board has explicitly stated no intention to implement the reverse stock split in the 12-month period following the meeting.